Alnylam Pharmaceuticals (ALNY) vs Viatris (VTRS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Viatris (VTRS) has outperformed Alnylam Pharmaceuticals (ALNY) over the past year, gaining 74.9% versus a loss of 49.1%. Over five years, VTRS leads with a +29.6% price change compared with +11.6% for ALNY. Alnylam Pharmaceuticals is the larger company by market cap ($31.13 billion vs $20.26 billion), about 1.5 times the size.
On valuation, Viatris trades at a lower forward P/E (6.6x vs 18.7x for Alnylam Pharmaceuticals). Viatris pays a dividend yielding 2.72%, while Alnylam Pharmaceuticals does not currently pay one. Alnylam Pharmaceuticals converts more of its revenue into profit, with a net margin of 8.4% versus -24.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALNY | VTRS |
|---|---|---|
| Share price | $232.68 | $17.64 |
| Market cap | $31.13B | $20.26B |
| 1-day change | +3.63% | +1.15% |
| YTD return | -41.49% | +40.08% |
| 1-year return | -49.08% | +74.92% |
| 5-year return | +11.57% | +29.57% |
| P/E ratio (TTM) | 37.83 | — |
| Forward P/E | 18.73 | 6.60 |
| EPS (TTM) | $6.15 | $-0.36 |
| Dividend yield | 0.00% | 2.72% |
| Annual dividend | $0.00 | $0.48 |
| Revenue (latest FY) | $3.71B | $14.30B |
| Revenue growth (YoY) | +65.19% | -2.98% |
| Net income (latest FY) | $313.75M | $-3.51B |
| Gross margin | 81.77% | 35.06% |
| Operating margin | 13.51% | -18.62% |
| Net margin | 8.45% | -24.58% |
| 52-week high | $495.55 | $18.43 |
| 52-week low | $197.81 | $9.73 |
| Distance from 52-week high | -53.05% | -4.29% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +59.50% | +11.68% |
| Average volume | 1.77M | 9.28M |
| Shares outstanding | 133.81M | 1.15B |
| Employees | 2,500 | 30,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VTRS has outperformed ALNY by 124.0 percentage points over the past year.
- Viatris offers a meaningfully higher dividend yield (2.72% vs 0.00%).
- Alnylam Pharmaceuticals is more profitable, keeping 8.4 cents of every revenue dollar as net income versus -24.6 cents for Viatris.
- Alnylam Pharmaceuticals grew revenue faster in its latest fiscal year (+65.19% vs -2.98%).
About Alnylam Pharmaceuticals
ALNY stock →Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,500 employees
About Viatris
VTRS stock →Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets.
Health Care · Biotechnology: Pharmaceutical Preparations · 30,000 employees
ALNY vs VTRS FAQ
Which is bigger, Alnylam Pharmaceuticals or Viatris?
Alnylam Pharmaceuticals (ALNY) is larger, with a market capitalization of $31.13B compared with $20.26B for Viatris (VTRS).
Which stock has performed better over the past year, ALNY or VTRS?
VTRS returned +74.92% over the past 12 months, compared with -49.08% for ALNY (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Alnylam Pharmaceuticals or Viatris?
Viatris pays a dividend yielding 2.72%, while Alnylam Pharmaceuticals does not currently pay a regular dividend.
Are Alnylam Pharmaceuticals and Viatris in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.